Cargando…

Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors

Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint swelling and destruction that leads to severe disability. There are no clear guidelines regarding the order of therapies. Gathering data on treatment patterns outside of a clinical trial setting can provid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Xue, Lobo, Francis, Broder, Michael S., Chang, Eunice, Gibbs, Sarah N., Ridley, David J., Yermilov, Irina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Columbia Data Analytics, LLC 2021
Materias:	Autoimmune Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133796/ https://www.ncbi.nlm.nih.gov/pubmed/34046511 http://dx.doi.org/10.36469/jheor.2021.23684

Ejemplares similares

The Economic and Humanistic Burden of Pediatric-Onset Multiple Sclerosis
por: Greene, Nupur, et al.
Publicado: (2022)

Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response
por: Valli, Atte, et al.
Publicado: (2022)

A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate
por: Fakhouri, Walid, et al.
Publicado: (2020)

Biologic Cost per Effectively Treated Rheumatoid Arthritis Patient in a Large Managed Care Population: A Retrospective Cohort Study
por: Gu, Tao, et al.
Publicado: (2015)

Functional Analysis of a Complement Polymorphism (rs17611) Associated with Rheumatoid Arthritis
por: Giles, Joanna L., et al.
Publicado: (2015)

Inflammaging as a link between autoimmunity and cardiovascular disease: the case of rheumatoid arthritis
por: Santos-Moreno, Pedro, et al.
Publicado: (2021)

A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models
por: Cho, Somi, et al.
Publicado: (2022)

Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren’s syndrome shared megakaryocyte expansion in peripheral blood
por: Wang, Yukai, et al.
Publicado: (2022)

New pro-inflammatory cytokine IL-40 is produced by activated neutrophils and plays a role in the early stages of seropositive rheumatoid arthritis
por: Navrátilová, Adéla, et al.
Publicado: (2023)

A novel monoclonal antibody with improved FcγR blocking ability demonstrated non-inferior efficacy compared to IVIG in cynomolgus monkey ITP model at considerably lower dose
por: Nakajima-Kato, Yuko, et al.
Publicado: (2022)

The longitudinal loss of islet autoantibody responses from diagnosis of type 1 diabetes occurs progressively over follow-up and is determined by low autoantibody titres, early-onset, and genetic variants
por: Williams, C L, et al.
Publicado: (2022)

Combination therapy of a TRPV2 agonist with a TNF inhibitor achieves sustained suppression of disease severity and reduced joint damage
por: Laragione, Teresina, et al.
Publicado: (2022)

CTLA4, SH2B3, and CLEC16A diversely affect the progression of early islet autoimmunity in relatives of Type 1 diabetes patients
por: Vandewalle, Julie, et al.
Publicado: (2023)

Diagnostic markers and potential therapeutic agents for Sjögren’s syndrome screened through multiple machine learning and molecular docking
por: Zhou, Liqing, et al.
Publicado: (2023)

IgE autoantibodies in serum and skin of non‐bullous and bullous pemphigoid patients
por: Lamberts, A., et al.
Publicado: (2020)

Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy
por: Leipe, Jan, et al.
Publicado: (2018)

Loss of the Protein Tyrosine Phosphatase PTPN22 Reduces Mannan-Induced Autoimmune Arthritis in SKG Mice
por: Sood, Shatakshi, et al.
Publicado: (2016)

Human epididymis protein 4 (HE4) is a novel biomarker for fibrosis in IgG4-related disease and can predict poor prognosis
por: Yan, Songxin, et al.
Publicado: (2022)

Metabolites and metabolic pathways associated with rheumatoid arthritis and systemic lupus erythematosus
por: Duarte-Delgado, Nancy P., et al.
Publicado: (2022)

Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids
por: Hu, Yanhua, et al.
Publicado: (2018)

Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey
por: Maurer, M., et al.
Publicado: (2018)

Real-World Assessment of Weight Change in People with HIV-1 After Initiating Integrase Strand Transfer Inhibitors or Protease Inhibitors
por: Chen, Yen-Wen, et al.
Publicado: (2020)

Cost-effectiveness Analysis of Hypoallergenic Milk Formulas for the Management of Cow’s Milk Protein Allergy in the United Kingdom
por: Martins, Rui, et al.
Publicado: (2021)

Comparing the Fiscal Consequences of Controlled and Uncontrolled Osteoarthritis Pain Applying a UK Public Economic Perspective
por: Martins, Rui, et al.
Publicado: (2021)

Clinical and Cost Burden of Primary Sjögren’s Syndrome: Descriptive Analysis Using a US Administrative Claims Database
por: Perera, Sue, et al.
Publicado: (2018)

Complement C4 Copy Number Variation is Linked to SSA/Ro and SSB/La Autoantibodies in Systemic Inflammatory Autoimmune Diseases
por: Lundtoft, Christian, et al.
Publicado: (2022)

Managing Cow’s Milk Protein Allergy in Indonesia: A Cost-effectiveness Analysis of Hypoallergenic Milk Formulas from the Private Payers’ Perspective
por: Paquete, Ana Teresa, et al.
Publicado: (2022)

Development of a Conceptual Model to Understand Disease Burden in Patients With Systemic Lupus Erythematosus and Organ Damage
por: Broderick, Lynne, et al.
Publicado: (2023)

A Retrospective Patient Chart Review and Survey in Patients with Cryopyrin-associated Periodic Syndromes Treated with Anakinra
por: Lachmann, Helen J., et al.
Publicado: (2013)

The Cost-effectiveness of Celecoxib versus Non-steroidal Anti-inflammatory Drugs plus Proton-pump Inhibitors for Treating Osteoarthritis in Algeria
por: Hammoumraoui, Nadir, et al.
Publicado: (2013)

Lymph node biopsy analysis reveals an altered immunoregulatory balance already during the at‐risk phase of autoantibody positive rheumatoid arthritis
por: Ramwadhdoebe, Tamara H., et al.
Publicado: (2016)

Granulocyte‐augmented chemokine production induced by type II collagen containing immune complexes is mediated via TLR4 in rheumatoid arthritis patients
por: Manivel, Vivek Anand, et al.
Publicado: (2016)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network
por: Salmon, Jean-Hugues, et al.
Publicado: (2020)

Impact of anti-citrullinated protein antibody on tumor necrosis factor inhibitor or abatacept response in patients with rheumatoid arthritis
por: Tymms, Kathleen, et al.
Publicado: (2021)

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
por: Westhovens, R, et al.
Publicado: (2009)

Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities
por: Cappelli, Laura C, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_r3f9o0v5nieliiphsdncjpmfjf